Puma Biotech (PBYI) Reports Q3 EPS of $0.17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Puma Biotech (PBYI) Reports Q3 EPS of $0.17
November 2, 2018 9:18 AM EDT
BofA/Merrill Lynch analyst Ying Huang downgraded Puma Biotechnology (NASDAQ: PBYI) from Buy to Underperform with a price target of $25.00 (from $92.00).
The analyst cites weak Nerlynx sales for the dramatic reversal of opinion.
For an analyst ratings summary and ratings history... More
November 2, 2018 5:55 AM EDT
JPMorgan analyst Cory Kasimov downgraded Puma Biotechnology (NASDAQ: PBYI) from Neutral to Underweight with a price target of $23.00 (from $83.00).
The analyst is incrementally more negative citing the "significantly tempered" expectations on Nerlynx.
For an analyst ratings summary and ratings history on... More
November 2, 2018 4:32 AM EDT
Barclays analyst Gena Wang downgraded Puma Biotechnology (NASDAQ: PBYI) from Equalweight to Underweight with a price target of $29.00 (from $72.00).
The analyst steps aside citing the Q3 revenue miss along with a lack of growth clarity on Nerlynx.
For an analyst ratings... More
